Literature DB >> 22105547

Management of obstetric antiphospholipid syndrome.

Guilherme Ribeiro Ramires de Jesus1, Flavia Cunha dos Santos, Camila Souto Oliveira, Wallace Mendes-Silva, Nilson Ramires de Jesus, Roger Abramino Levy.   

Abstract

Recurrent early miscarriages (excluding chromosomal anomalies), late fetal loss, and maternal thrombosis are characteristic of obstetric antiphospholipid syndrome (APS). Obstetric complications such as preeclampsia, fetal growth restriction, premature delivery, and fetal death also occur in higher frequency in APS patients than in the general population. A high-risk obstetric center is needed for proper evaluation of and intervention with pregnant women with APS. Association with lupus carries additional risk of thrombosis when antiphospholipid antibodies (aPLs) are present. Gestational results with live births are improved to about 80% when antithrombotic therapy is used, but failure in 20% to 30% of the cases despite correct treatment with low-dose aspirin with or without heparin reveals new pathways for pregnancy loss in APS and unmet needs. At the moment, there is no recommendation to investigate patients with infertility for the presence of aPLs.

Entities:  

Mesh:

Year:  2012        PMID: 22105547     DOI: 10.1007/s11926-011-0218-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  65 in total

Review 1.  Systemic lupus erythematosus and pregnancy.

Authors:  Munther A Khamashta
Journal:  Best Pract Res Clin Rheumatol       Date:  2006-08       Impact factor: 4.098

2.  Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis.

Authors:  Lucie Opatrny; Michéle David; Susan R Kahn; Ian Shrier; Evelyne Rey
Journal:  J Rheumatol       Date:  2006-10-01       Impact factor: 4.666

3.  Obstetric antiphospholipid syndrome: still a challenge.

Authors:  R A Levy; G R R Jesús; N R Jesús
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

4.  Safety of IVF under anticoagulant therapy in patients at risk for thrombo-embolic events.

Authors:  Yoav Yinon; Rachel Pauzner; Mordechai Dulitzky; Shai E Elizur; Jehoshua Dor; Adrian Shulman
Journal:  Reprod Biomed Online       Date:  2006-03       Impact factor: 3.828

Review 5.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant.

Authors:  M Empson; M Lassere; J Craig; J Scott
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

Review 6.  Pregnancy and rheumatic disease: "by the book" or "by the doc".

Authors:  Stephanie O Keeling; Anna E Oswald
Journal:  Clin Rheumatol       Date:  2008-11-06       Impact factor: 2.980

Review 7.  [Ovulation induction therapy and systemic lupus erythematosus].

Authors:  Du Lê Thi Huong; Bertrand Wechsler; Jean-Charles Piette
Journal:  Ann Med Interne (Paris)       Date:  2003-02

8.  Primary antiphospholipid syndrome: pregnancy outcome in a portuguese population.

Authors:  Fatima Serrano; Isabel Nogueira; Augusta Borges; Jorge Branco
Journal:  Acta Reumatol Port       Date:  2009 Jul-Sep       Impact factor: 1.290

9.  Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.

Authors:  Mary D Stephenson; Penny J Ballem; Peter Tsang; Sue Purkiss; Stephanie Ensworth; Edwina Houlihan; Mary H H Ensom
Journal:  J Obstet Gynaecol Can       Date:  2004-08

Review 10.  Novel considerations in the pathogenesis of the antiphospholipid syndrome: involvement of the tissue factor pathway of blood coagulation.

Authors:  Murray Adams
Journal:  Semin Thromb Hemost       Date:  2008-04       Impact factor: 4.180

View more
  7 in total

Review 1.  Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?

Authors:  Guilherme R de Jesús; Gustavo Rodrigues; Nilson R de Jesús; Roger A Levy
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 2.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

3.  Clinical features associated with pregnancy outcomes in women with positive antiphospholipid antibodies and previous adverse pregnancy outcomes: a real-world prospective study.

Authors:  Xinyi Li; Xiaoli Deng; Hongji Duan; Lin Zeng; Jiansuo Zhou; Chang Liu; Xiaoyue Guo; Xiangyuan Liu
Journal:  Clin Rheumatol       Date:  2020-06-08       Impact factor: 2.980

Review 4.  Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?

Authors:  Ilaria Mormile; Francescopaolo Granata; Alessandra Punziano; Amato de Paulis; Francesca Wanda Rossi
Journal:  Biomedicines       Date:  2021-02-01

Review 5.  Obstetric Antiphospholipid Syndrome From the Perspective of a Rheumatologist.

Authors:  Juan Camilo Santacruz; Marta Juliana Mantilla; Igor Rueda; Sandra Pulido; Gustavo Rodríguez; John Londono
Journal:  Cureus       Date:  2022-01-10

Review 6.  Understanding and Managing Pregnancy in Patients with Lupus.

Authors:  Guilherme Ramires de Jesus; Claudia Mendoza-Pinto; Nilson Ramires de Jesus; Flávia Cunha Dos Santos; Evandro Mendes Klumb; Mario García Carrasco; Roger Abramino Levy
Journal:  Autoimmune Dis       Date:  2015-07-12

Review 7. 

Authors:  Andreas Funke; Adriana Danowski; Danieli Castro Oliveira de Andrade; Jozelia Rêgo; Roger Abramino Levy
Journal:  J Vasc Bras       Date:  2017 Apr-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.